Totus Medicines Advances TOS-358 Development with New Leadership
Totus Medicines Completes Phase 1 Study of TOS-358
Totus Medicines has successfully completed a Phase 1 dose-escalation study for TOS-358, a novel covalent PI3K? selective therapy. The study demonstrated significant clinical activity and a remarkable 95% target engagement at doses as low as 5 mg BID. Notably, there were no grade 3 or 4 toxicities reported, indicating a favorable safety profile for this promising treatment.
Initiation of an Expansion Trial
Following the encouraging results from the initial study, Totus Medicines is excited to announce the initiation of an expansion trial. This new phase will evaluate TOS-358 in patients with various solid tumors, including breast, endometrial, urothelial, and head and neck cancers at doses of 5 and 8 mg BID. The expansion study marks a significant step forward for the company as it broaden its research efforts into critical areas of unmet medical need.
Appointment of Zelanna Goldberg as Chief Medical Officer
In a strategic move to bolster its leadership team, Totus Medicines has appointed Dr. Zelanna Goldberg as Chief Medical Officer. Dr. Goldberg brings extensive experience in oncology drug development, having held prominent positions at several leading biopharma companies. Her expertise will be invaluable as Totus advances its clinical-stage programs.
Comments from Leadership
Nassim Usman, Ph.D., President & CEO of Totus Medicines, expressed optimism regarding the recent study accomplishments, stating, "The Phase 1 study has established TOS-358 as a leading candidate in the PI3K? inhibitor landscape, and we are eager to explore its potential in combination therapies." Dr. Goldberg echoed these sentiments, emphasizing her enthusiasm about joining the Totus team and contributing to the development of TOS-358.
About Totus Medicines
Totus Medicines is at the forefront of small molecule drug discovery, utilizing an innovative approach that combines DNA-encoded covalent library technology with artificial intelligence and machine learning. The company's advanced platform enables the screening of hundreds of millions of drug candidates simultaneously, paving the way for breakthroughs in previously challenging therapeutic areas. Currently, Totus is progressing TOS-358 through a Phase 1b clinical trial while also developing multiple selective covalent inhibitors.
Contact Information
For more details about their work and progress, interested parties may reach out to Totus at ir@totusmedicines.com. For external communications, please contact Brian Mullen from LifeSci Advisors at +1.203.461.1175.
Frequently Asked Questions
What is TOS-358?
TOS-358 is a covalent PI3K? selective therapy developed by Totus Medicines, aimed at treating various solid tumors.
What does the Phase 1 study of TOS-358 demonstrate?
The Phase 1 study showed a 95% target engagement and no severe toxicities, indicating a favorable safety profile.
What types of cancers is the expansion trial targeting?
The expansion trial will evaluate TOS-358 in breast, endometrial, urothelial, and head and neck cancers.
Who is Dr. Zelanna Goldberg?
Dr. Zelanna Goldberg is the newly appointed Chief Medical Officer at Totus Medicines, bringing extensive oncology experience.
What is the focus of Totus Medicines?
Totus Medicines is focused on discovering and developing innovative small molecule drugs using advanced techniques and AI.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.